Literature DB >> 12805432

Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes.

Carolyn Lutzko1, Dinithi Senadheera, Dianne Skelton, Denise Petersen, Donald B Kohn.   

Abstract

In the present studies we developed lentivirus vectors with regulated, consistent transgene expression in B lymphocytes by incorporating the immunoglobulin heavy chain enhancer (E micro ) with and without associated matrix attachment regions (E micro MAR) into lentivirus vectors. Incorporation of these fragments upstream of phosphoglycerate kinase (PGK) or cytomegalovirus promoters resulted in a two- to threefold increase in enhanced green fluorescent protein (EGFP) mean fluorescence intensity (MFI) in B-lymphoid but not T-lymphoid, myeloid, fibroblast, or carcinoma cell lines. A 1-log increase in EGFP expression was observed in B-lymphoid cells (but not myeloid cells) differentiated from human CD34(+) progenitors in vitro transduced with E micro - and E micro MAR-containing lentivectors. Lastly, we evaluated the expression from the E micro MAR element in mice 2 to 24 weeks posttransplant with transduced hematopoietic stem cells. In mice receiving vectors with the E micro and E micro MAR elements upstream of the PGK promoter, there was a 2- to 10-fold increase in EGFP expression in B cells (but not other cell types). Evaluation of the coefficient of variation of expression among different cell types demonstrated that consistent, position-independent transgene expression was observed exclusively in B cells transduced with the E micro MAR-containing vector and not other cells types or vectors. Proviral genomes with the E micro MAR element had increased chromatin accessibility, which likely contributed to the position independence of expression in B lymphocytes. In summary, incorporation of the E micro MAR element in lentivirus vectors resulted in enhanced, position-independent expression in primary B lymphocytes. These vectors provide a useful tool for the study of B-lymphocyte biology and the development of gene therapy for disorders affecting B lymphocytes, such as immune deficiencies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805432      PMCID: PMC164820          DOI: 10.1128/jvi.77.13.7341-7351.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Variegated expression of the endogenous immunoglobulin heavy-chain gene in the absence of the intronic locus control region.

Authors:  D Ronai; M Berru; M J Shulman
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells.

Authors:  Yan Cui; Jonathan Golob; Erin Kelleher; Zhaohui Ye; Drew Pardoll; Linzhao Cheng
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

3.  The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development.

Authors:  J D Alvarez; D H Yasui; H Niida; T Joh; D Y Loh; T Kohwi-Shigematsu
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

4.  Efficient lentiviral transduction of liver requires cell cycling in vivo.

Authors:  F Park; K Ohashi; W Chiu; L Naldini; M A Kay
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

5.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

6.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.

Authors:  C May; S Rivella; J Callegari; G Heller; K M Gaensler; L Luzzatto; M Sadelain
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

7.  Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.

Authors:  Chad May; Stefano Rivella; Amy Chadburn; Michel Sadelain
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

8.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

Review 9.  The transcription factor, Bright, and immunoglobulin heavy chain expression.

Authors:  C F Webb
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

Review 10.  Role of Bruton's tyrosine kinase in B cell development.

Authors:  A Maas; R W Hendriks
Journal:  Dev Immunol       Date:  2001
View more
  14 in total

1.  Targeting lentiviral vectors to specific cell types in vivo.

Authors:  Lili Yang; Leslie Bailey; David Baltimore; Pin Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

2.  Generation of plasmid vectors expressing FLAG-tagged proteins under the regulation of human elongation factor-1α promoter using Gibson assembly.

Authors:  Petar N Grozdanov; Clinton C MacDonald
Journal:  J Vis Exp       Date:  2015-02-09       Impact factor: 1.355

3.  A major isoform of the E3 ubiquitin ligase March-I in antigen-presenting cells has regulatory sequences within its gene.

Authors:  Sunil Kaul; Sharad K Mittal; Paul A Roche
Journal:  J Biol Chem       Date:  2018-01-29       Impact factor: 5.157

4.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

5.  Development of lentiviral vectors with regulated respiratory epithelial expression in vivo.

Authors:  Benjamin Hendrickson; Dinithi Senadheera; Suparna Mishra; Kim Chi T Bui; Xingchao Wang; Belinda Chan; Denise Petersen; Karen Pepper; Carolyn Lutzko
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

6.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

Review 7.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

8.  Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors.

Authors:  T E Taher; C Tulone; R Fatah; F D'Acquisto; D J Gould; R A Mageed
Journal:  Gene Ther       Date:  2008-03-20       Impact factor: 5.250

9.  Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule.

Authors:  Steven Froelich; Leslie Ziegler; Katie Stroup; Pin Wang
Journal:  Biotechnol Bioeng       Date:  2009-09-01       Impact factor: 4.530

10.  Targeting lentiviral vectors to antigen-specific immunoglobulins.

Authors:  Leslie Ziegler; Lili Yang; Kye il Joo; Haiguang Yang; David Baltimore; Pin Wang
Journal:  Hum Gene Ther       Date:  2008-09       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.